LA JOLLA, Calif.--(BUSINESS WIRE)--Jan. 31, 2022--
DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that its management will participate at the following conferences:
11th Annual SVB Leerink Global Healthcare Conference
Participating in investor meetings on February 16-17, 2022
BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Presenting on Wednesday, February 16, 2022 at 1:00 p.m. Eastern Time
The webcast link is available only for those who are attending the BTIG conference.
DermTech is a leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by our non-invasive skin genomics platform. DermTech's mission is to transform dermatology with our non-invasive skin genomics platform, to democratize access to high quality dermatology care, and to improve the lives of millions. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech markets and develops products that facilitate the early detection of skin cancers and is developing products that assess inflammatory diseases and customize drug treatments. For additional information on DermTech, please visit DermTech's investor relations site at: www.dermtech.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220131005207/en/
Press and Media:
Caroline Corner, PhD
Source: DermTech, Inc.